Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.33 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1397163 | 0.82 | CHRNA7 (0.42) | MAOBKDM1ACHRNA7 | |
| SCHEMBL2196174 | 0.79 | CYP2C19 (0.34) | MAOBCYP2C19 | |
| SCHEMBL7703173 | 0.72 | PAM (0.46) | MAOBDPP4 | |
| SCHEMBL4374764 | 0.71 | SLC6A4 (0.33) | CHRNA7 | |
| SCHEMBL5357440 | 0.66 | MEN1 (0.40) | MAOB | |
| SCHEMBL152753 | 0.65 | — | — | |
| SCHEMBL9011441 | 0.63 | MAOB (0.44) | MAOB | |
| Styrene SCHEMBL15477029 | 0.63 | ALDH1A1 (0.50) | — | |
| SCHEMBL175339 | 0.63 | MAOB (0.55) | MAOB | |
| SCHEMBL367481 | 0.63 | MAOB (0.55) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207456-B | Latent acids and their use | 巴斯夫欧洲公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| EP-2539316-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2019-10-23 | — | — | EP | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| EP-1595182-B1 | HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | BASF SE (DE) | 2015-09-30 | — | — | EP | disclosed |
| EP-1769286-B1 | OXIME DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2015-09-09 | — | — | EP | disclosed |
| EP-2539316-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2013-01-02 | — | — | EP | disclosed |
| WO-2011104127-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2011-09-01 | — | — | WO | disclosed |
| EP-2349993-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-08-03 | — | — | EP | disclosed |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-1595182-A2 | HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| EP-1472576-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004074242-A2 | HALOGENATED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2004-09-02 | — | — | WO | disclosed |
| EP-1392675-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| EP-1344109-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003067332-A2 | SULFONATE DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2003-08-14 | — | — | WO | disclosed |
| EP-1320785-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | Ciba SC Holding AG (CH) | 2003-06-25 | — | — | EP | disclosed |
| WO-2002098870-A1 | SUBSTITUTED OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002046507-A2 | ONIUM SALTS AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002025376-A2 | OXIME DERIVATIVES AND THE USE THEREOF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | MAOB 510/4885DPP4 4371/4885KDM1A 1664/4885 |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | NR2E3, HCAR3, HRH4 | MAOB 3321/4885DPP4 4538/4885KDM1A 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.